施贵宝公司首次将口服丙肝联合药物推向市场

关键词:施贵宝,丙肝,联合给药

2013年11月5日讯 /生物谷BIOON/ --制药巨头施贵宝公司研发的治疗丙肝的联合口服药物在日本获准上市,这也是第一种上市的类似药物。多年来丙肝的治疗主要是使用干扰素药物,然而在丙肝患者中有相当多的个体对干扰素耐受或过敏。这也使丙肝新疗法的开发显得更为紧迫。目前还有一些公司也在研究类似药物,如Gilead公司等。(生物谷Bioon.com)

详细英文报道:

In a notable first, Bristol-Myers Squibb ($BMY) has filed a combination of daclatasvir and asunaprevir for approval to treat hepatitis C in Japan--the first all-oral combo in a regulatory package that excludes interferon. Bristol-Myers has been testing the combo in patients who either couldn't tolerate interferon--a large group--or were resistant to the treatments now available. The biopharma company is one step behind Gilead ($GILD) in the U.S., where its rival is expected to nab a quick approval for sofosbuvir after a unanimous vote in its favor by an FDA panel on stellar late-stage data. Gilead is following up with a combo package of its own, while AbbVie ($ABBV) plays catch-up with its late-stage effort.

 

(责任编辑:lishuheng)

分享到:
小编提示:87%用户都在生物谷APP上阅读,扫描立刻下载!

您还可以这样阅读

微信扫一扫,体验新式阅读

打开微信扫描二维码

生物谷微信账号:bioonnews

我们提供多种阅读途径供您选择,随时随地掌握医药生物领域最新资讯。

生物谷微信二维码

    相关资料

    欢迎行业评论、发现、小道消息、官方爆料、采访约稿

    我要投稿   下载App支持编辑